AnPac Bio-Medical Science Co., Ltd.
ANPC · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $6 | $3 | $2 |
| % Growth | -93.2% | 97% | 64.9% | – |
| Cost of Goods Sold | $0 | $1 | $1 | $1 |
| Gross Profit | -$0 | $5 | $2 | $1 |
| % Margin | -7.6% | 78% | 70.6% | 55.4% |
| R&D Expenses | $2 | $4 | $2 | $2 |
| G&A Expenses | $27 | $20 | $14 | $10 |
| SG&A Expenses | $30 | $23 | $16 | $13 |
| Sales & Mktg Exp. | $3 | $4 | $2 | $3 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $32 | $27 | $18 | $16 |
| Operating Income | -$32 | -$22 | -$36 | -$15 |
| % Margin | -7,315.6% | -345.1% | -1,116.6% | -738.6% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$32 | -$22 | -$36 | -$15 |
| Tax Expense | -$0 | -$2 | -$2 | -$0 |
| Net Income | -$32 | -$20 | -$34 | -$15 |
| % Margin | -7,394.3% | -315.9% | -1,045.1% | -757.1% |
| EPS | -16.9 | -13.95 | -39.2 | -17.22 |
| % Growth | -21.1% | 64.4% | -127.6% | – |
| EPS Diluted | -16.9 | -13.95 | -39.2 | -17.22 |
| Weighted Avg Shares Out | 2 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$1 | $0 | $22 | -$0 |
| EBITDA | -$33 | -$22 | -$15 | -$15 |
| % Margin | -7,474.1% | -338.7% | -452.4% | -757.1% |